Evidence map›Paper›PMID 21904682›Full record

ArticleJournal of drug delivery2012

Lipoplatin formulation review article.

G P Stathopoulos, T Boulikas

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug delivery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 215 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Liposomal Formulations of Metallodrugs for Cancer Therapy.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Nanomedicines in the treatment of colon cancer: a focus on metallodrugs.Drug delivery and translational research · 2022
    Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

G P StathopoulosFirst Oncology Clinic, Errikos Dunant Hospital, Athens, Greece.
T Boulikas
Henry Dunant Hospital · GRRegulon (Greece) · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications. For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.

Identifiers

PMID21904682
PMCPMC3166721
OpenAlexW2024007204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.